Scarica l'app Stockscreener
1.515
7.62%
-0.125
Dopo l'orario di chiusura:
1.53
0.015
+0.99%
Precedente Chiudi:
$1.64
Aprire:
$1.61
Volume 24 ore:
1.09M
Relative Volume:
1.74
Capitalizzazione di mercato:
$2.23M
Reddito:
$502.40K
Utile/perdita netta:
$-7.91M
Rapporto P/E:
-0.1519
EPS:
-9.972
Flusso di cassa netto:
$-4.32M
1 W Prestazione:
-41.95%
1M Prestazione:
-26.81%
6M Prestazione:
-63.41%
1 anno Prestazione:
-89.20%
Intervallo 1D:
$1.50
$1.63
Intervallo di 1 settimana:
$1.50
$2.64
Portata 52W:
$1.41
$35.99
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
Nome
60 Degrees Pharmaceuticals Inc
Settore
Industria
Telefono
202-327-5422
Indirizzo
1025 CONNECTICUT AVENUE NW, WASHINGTON
Confronta SXTP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
1.515 | 3.62M | 502.40K | -7.91M | -4.32M | -9.972 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
60 Degrees Pharmaceuticals Inc Borsa (SXTP) Ultime notizie
60 Degrees Pharmaceuticals to study tafenoquine against Lyme disease By Investing.com - Investing.com India
60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria - The Manila Times
60 Degrees Pharmaceuticals to study tafenoquine against Lyme disease - Investing.com
Major Breakthrough: Anti-Malaria Drug Tafenoquine Being Tested for Lyme Disease Treatment - Stock Titan
60 Degrees Pharmaceuticals' Warrant Gambit: Balancing Liquidity and Longevity - AInvest
60 Degrees Pharmaceuticals closes $5 million public offering By Investing.com - Investing.com South Africa
60 Degrees Pharmaceuticals closes $5 million public offering - Investing.com Australia
60 Degrees Pharmaceuticals Secures $5 Million in Public Offering - AInvest
60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering - Yahoo Finance
Form 424B4 60 DEGREES PHARMACEUTICA - StreetInsider
Trade Desk Shares Surge 15% Amid S&P 500 Inclusion - AInvest
Why 60 Degrees Pharmaceuticals Inc. Equity Warrant stock attracts strong analyst attentionProfitable Yet Secure Picks - Newser
60 Degrees Pharmaceuticals Prices $10 Million Public Offering - citybiz
How 60 Degrees Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Real-Time Monitoring - Newser
SXTP Crashes 21%—What’s Behind the Unraveling of 60 Degrees Pharma? - AInvest
SXTP Stock’s Upward Trend: What Lies Ahead? - StocksToTrade
60 Degrees Pharmaceuticals' $10M Raise: A High-Risk Gamble on Capital Efficiency? - AInvest
60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering - The Manila Times
What makes 60 Degrees Pharmaceuticals Inc. stock price move sharplyFree Step-by-Step Investment Guide - Newser
60 Degrees Pharmaceuticals Secures Up to $10M Funding: New Capital Injection for Infectious Disease Breakthroughs - Stock Titan
Why 60 Degrees Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
What makes Recursion Pharmaceuticals Inc. stock price move sharplyFree Smart Investment Opportunities - Newser
Why BridgeBio Pharma Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
60 Degrees Pharma targets $245 million market for babesiosis treatment - Investing.com Australia
60 Degrees Pharma targets $245 million market for babesiosis treatment By Investing.com - Investing.com South Africa
Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission - Stock Titan
Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
60 Degrees Pharmaceuticals Inc (SXTP) Stock Soars 77.83% on MUMS Designation Plans - AInvest
Breakthrough Babesiosis Drug ARAKODA Targets $1.1B Market Opportunity, FDA Filing Next Year - Stock Titan
How 60 Degrees Pharmaceuticals Inc. Equity Warrant stock performs during market volatilityWeekly Big Movers - Newser
60 Degrees Pharmaceuticals’ (SXTP) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Sypris Solutions (NASDAQ:SYPR) vs. IES (NASDAQ:IESC) Head-To-Head Analysis - Defense World
Reviewing International Flavors & Fragrances (NYSE:IFF) and H. B. Fuller (NYSE:FUL) - Defense World
New Semiconductor SPAC Launches $100M IPO: Silver Pegasus Targets Tech Acquisitions - Stock Titan
60 Degrees Pharmaceuticals: Leveraging MUMS Designation to Tackle Canine Babesiosis and Drive Growth - AInvest
60 Degrees to Submit FDA MUMS Request for Tafenoquine in Canine Babesiosis - MarketScreener
60 Degrees Pharmaceuticals stock surges on canine babesiosis treatment plans - Investing.com
First FDA-Approved Oral Treatment for Dangerous Tick-Borne Dog Disease Could Be Coming in 2025 - Stock Titan
Biotech Giant Vertex Pharmaceuticals Schedules Q2 2025 Earnings CallKey Details for Investors - Stock Titan
Trinity Capital Sets Q2 2025 Earnings Call: Live Webcast and Phone Access Available - Stock Titan
Breakthrough Brain Cancer Drug REYOBIQ Achieves 80% Tumor Reduction in Phase 1 Trial, Advances to Next Stage - Stock Titan
Eupraxia's Revolutionary EoE Drug Enters Critical Phase 2b Trial: Direct Injection Method Shows Promise - Stock Titan
Eton's New Pediatric Drug Solution Advances Toward FDA Approval, Targeting $1B Market Opportunity - Stock Titan
GAMMA Investing LLC Grows Stock Position in M/I Homes, Inc. (NYSE:MHO) - Defense World
FDA Breakthrough: First-Ever Oral Drug for HAE Attacks Ends Decade of Injectable-Only Treatments - Stock Titan
Prudential Financial Sets Q2 Earnings Date: $1.5T Asset Manager Reports July 30 - Stock Titan
Prospect Capital Expands Consumer Credit Portfolio with Strategic $115M QC Holdings Buyout - Stock Titan
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
Xenon Makes Major League Move: Dual Russell Index Inclusion Opens Door to $10.6T Investment Pool - Stock Titan
Major Breakthrough: Corvus Expands Atopic Dermatitis Drug Development into Chinese Market with New Trial Approval - Stock Titan
First Patient Shows Zero Toxicity in CERo's Groundbreaking Cancer Immunotherapy Trial - Stock Titan
60 Degrees Pharmaceuticals Inc Azioni (SXTP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
60 Degrees Pharmaceuticals Inc Azioni (SXTP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| XU CHERYL | Director |
Dec 13 '24 |
Buy |
1.56 |
6,000 |
9,375 |
52,078 |
| XU CHERYL | Director |
Dec 12 '24 |
Buy |
1.82 |
5,000 |
9,125 |
46,078 |
| XU CHERYL | Director |
Dec 16 '24 |
Buy |
1.45 |
2,000 |
2,900 |
54,078 |
| DOW GEOFFREY S | President and CEO |
Dec 09 '24 |
Buy |
1.27 |
35,823 |
45,563 |
94,580 |
| DOW GEOFFREY S | President and CEO |
Dec 06 '24 |
Buy |
1.20 |
20,579 |
24,672 |
58,757 |
| DOW GEOFFREY S | President and CEO |
Dec 05 '24 |
Buy |
1.11 |
17,549 |
19,520 |
38,178 |
| DOW GEOFFREY S | President and CEO |
Nov 21 '24 |
Buy |
0.91 |
3,500 |
3,195 |
20,629 |
| DOW GEOFFREY S | President and CEO |
Nov 19 '24 |
Buy |
0.90 |
2,500 |
2,248 |
16,129 |
| DOW GEOFFREY S | President and CEO |
Nov 20 '24 |
Buy |
0.92 |
1,000 |
924 |
17,129 |
| XU CHERYL | Director |
Aug 27 '24 |
Buy |
1.70 |
5,000 |
8,500 |
41,078 |
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):